PC
MNTA

Polar Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Polar Capital’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-240,462
Closed -$8M – 332
2020
Q2 		$8M Buy
+240,462
New +$7.66M 0.07% 187

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Polar Capital's MNTA Position: Q3 2020 in Review

Polar Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 240,462 shares — an estimated $8M sold.

Polar Capital first reported a position in MNTA in Q2 2020 and held it in 1 quarter. The position peaked at $8M in Q2 2020. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

  • Polar Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Polar Capital sold 240,462 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $8M.
  • Polar Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Polar Capital's Momenta Pharmaceuticals, Inc. position peaked at $8M in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.